排名前五的靶点	数量

CCKB(胆囊收缩素B受体)	2
PSMA(前列腺癌特异性膜抗原)	2
mGluR5(代谢型谷氨酸受体-5)	2
MAGL(单甘油酯脂肪酶)	1
HSP90(Heat shock 90kDa proteins)	1

关联

项与 Swiss Federal Institute of Technology 相关的药物

Debio-1124

靶点

CCKB

作用机制

CCKB拮抗剂 [+1]

在研机构

Paul Scherrer Institut PSI

原研机构

Debiopharm International SA

在研适应症

胃肠胰神经内分泌肿瘤 [+3]

非在研适应症

小细胞肺癌

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

[18F]-FPECMO

靶点

mGluR5

作用机制

mGluR5调节剂

在研机构

Swiss Federal Institute of Technology

原研机构

Swiss Federal Institute of Technology

在研适应症

神经系统疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

[18F]-FE-DABP688

靶点

mGluR5

作用机制

mGluR5调节剂

在研机构

Swiss Federal Institute of Technology

原研机构

Swiss Federal Institute of Technology

在研适应症-

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

275

项与 Swiss Federal Institute of Technology 相关的临床试验

NCT06426082 / Not yet recruitingN/AIIT

Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women

Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women.
Participant Population/Health Conditions: The study will involve 40 young, lean adult women.
Main Questions: The main questions this study aims to answer are:
Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)?
What is the secretory function of these adipocytes?
How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels?
Participants Will:
Be randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment.
Follow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention.
Undergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells.
Comparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.

开始日期2024-11-01

申办/合作机构

Universidad de Almería

[+2]

NCT06623721 / Not yet recruitingN/AIIT

Feasibility and Tolerance of Movement-activated Auricular Vagus Nerve Stimulation in Motor Rehabilitation

Rehabilitation engineering laboratory (RELab) at the ETH Zurich is recruiting participants with a motor function deficit for studying a novel non-invasive brain stimulation method that may be a promising approach for benefiting motor recovery after conditions like stroke, traumatic brain injury or spinal cord injury. The study will be conducted at the cereneo Hertenstein clinic. Participants with residual motor function deficit due to stroke or spine/brain injury will be undergoing typical neurorehabilitation procedures in addition to the use of the automatically controlled non-invasive Vagus nerve stimulation (taVNS).
This study will analyze the feasibility of this method before it can be used by doctors generally. More specifically, this study aims to test whether controlling taVNS with a wearable wrist-worn sensor during rehabilitation exercises for movement is both practical and safe. This stimulation works by involves sending tiny electric pulses to the outside of the ear after the wrist sensor detects movement. These pulses activate the auricular Vagus nerve and in turn the brain. Over the course of multiple rehabilitation procedures, taVNS may to help with the speed of motor recovery as shown with previous, manually controlled studies. The goal of this study is wants to see if the automatically controlled taVNSs method works well and doesn't cause any harm while people are doing their therapy exercises. If successful, in the future it could offer a new way to improve the recovery process movement for people with motor difficulties.

开始日期2024-10-21

申办/合作机构

Swiss Federal Institute of Technology

NCT06657677 / Not yet recruitingN/AIIT

Assessing the Immediate Increase in Serum Ferritin After Oral Iron Doses: an Experimental Study in Iron-deficient Women.

Serum ferritin is a key indicator of body iron stores and is widely used in monitoring iron status. However, oral iron doses can acutely elevate SF levels, potentially biasing assessments of iron stores during supplementation. This study aims to investigate the extent and duration of the acute iron-induced effect on serum ferritin, as well as its protein characteristics, following the administration of a single iron dose

开始日期2024-10-01

申办/合作机构

Swiss Federal Institute of Technology

100 项与 Swiss Federal Institute of Technology 相关的临床结果

登录后查看更多信息

0 项与 Swiss Federal Institute of Technology 相关的专利（医药）

登录后查看更多信息

54,120

项与 Swiss Federal Institute of Technology 相关的文献（医药）

2024-12-01·Clinical proteomics

Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA

Article

作者: Fort, Kyle L ; Gandhi, Tejas ; Laforte, Véronique ; Goetze, Sandra ; Levesque, Mitchell P ; Wollscheid, Bernd ; Albinus, Jonas B ; Robbiani, Damiano ; Reiter, Lukas ; Xuan, Yue ; van Drogen, Audrey

Abstract:

Background:

Clinical samples are irreplaceable, and their transformation into searchable and reusable digital biobanks is critical for conducting statistically empowered retrospective and integrative research studies. Currently, mainly data-independent acquisition strategies are employed to digitize clinical sample cohorts comprehensively. However, the sensitivity of DIA is limited, which is why selected marker candidates are often additionally measured targeted by parallel reaction monitoring.

Methods:

Here, we applied the recently co-developed hybrid-PRM/DIA technology as a new intelligent data acquisition strategy that allows for the comprehensive digitization of rare clinical samples at the proteotype level. Hybrid-PRM/DIA enables enhanced measurement sensitivity for a specific set of analytes of current clinical interest by the intelligent triggering of multiplexed parallel reaction monitoring (MSxPRM) in combination with the discovery-driven digitization of the clinical biospecimen using DIA. Heavy-labeled reference peptides were utilized as triggers for MSxPRM and monitoring of endogenous peptides.

Results:

We first evaluated hybrid-PRM/DIA in a clinical context on a pool of 185 selected proteotypic peptides for tumor-associated antigens derived from 64 annotated human protein groups. We demonstrated improved reproducibility and sensitivity for the detection of endogenous peptides, even at lower concentrations near the detection limit. Up to 179 MSxPRM scans were shown not to affect the overall DIA performance. Next, we applied hybrid-PRM/DIA for the integrated digitization of biobanked melanoma samples using a set of 30 AQUA peptides against 28 biomarker candidates with relevance in molecular tumor board evaluations of melanoma patients. Within the DIA-detected approximately 6500 protein groups, the selected marker candidates such as UFO, CDK4, NF1, and PMEL could be monitored consistently and quantitatively using MSxPRM scans, providing additional confidence for supporting future clinical decision-making.

Conclusions:

Combining PRM and DIA measurements provides a new strategy for the sensitive and reproducible detection of protein markers from patients currently being discussed in molecular tumor boards in combination with the opportunity to discover new biomarker candidates.

2024-12-01·JOURNAL OF HAZARDOUS MATERIALS

Interactions between microplastics and heavy metals in leachate: Implications for landfill stabilization process

Article

作者: Xi, Beidou ; Wang, Hui ; Jiang, Yu ; Chen, Jiabao ; Hui, Kunlong ; Yuan, Ying ; Huang, Zekai ; Li, Yanjiao ; Huo, Lin

The emission of microplastics and heavy metals in landfills has attracted widespread attention for its stabilization process. Microplastics have become carriers of heavy metals due to their adsorption properties, affecting their environmental behavior. However, the effects of landfill stabilization on the interaction between microplastics and heavy metals in leachate are ambiguous. This work explored the abundance characteristics of microplastics and heavy metals in leachate from 10 landfills in Beijing. Overall, the average abundance of microplastics was 196.3 items/L, dominated by small particle size (20-50 µm) and film microplastics. The levels of Cr and As were much higher than other heavy metals. The average abundance of microplastics and polymer types tended to decrease as the landfill stabilization proceeded, and the surface composition of microplastics became more complex. Statistical analysis revealed that the correlations between microplastics and heavy metals in the leachate of landfill stabilization presented significant parabolic characteristics, and Cr and As were more susceptible to landfill stabilization with significant positive correlation with a wide range of microplastics such as 20-30 µm. These results were intended to provide a scientific basis for the treatment and disposal of waste leachate and the synergistic prevention and control of new and traditional pollutants.

2024-12-01·Nano-micro letters

Recent Developments in Metallic Degradable Micromotors for Biomedical and Environmental Remediation Applications

Review

作者: Choi, Hongsoo ; Gual, Roger Sanchis ; Dutta, Sourav ; Nelson, Bradley J ; Chen, Xiangzhong ; Noh, Seungmin ; Pané, Salvador

Abstract:

Synthetic micromotor has gained substantial attention in biomedicine and environmental remediation. Metal-based degradable micromotor composed of magnesium (Mg), zinc (Zn), and iron (Fe) have promise due to their nontoxic fuel-free propulsion, favorable biocompatibility, and safe excretion of degradation products Recent advances in degradable metallic micromotor have shown their fast movement in complex biological media, efficient cargo delivery and favorable biocompatibility. A noteworthy number of degradable metal-based micromotors employ bubble propulsion, utilizing water as fuel to generate hydrogen bubbles. This novel feature has projected degradable metallic micromotors for active in vivo drug delivery applications. In addition, understanding the degradation mechanism of these micromotors is also a key parameter for their design and performance. Its propulsion efficiency and life span govern the overall performance of a degradable metallic micromotor. Here we review the design and recent advancements of metallic degradable micromotors. Furthermore, we describe the controlled degradation, efficient in vivo drug delivery, and built-in acid neutralization capabilities of degradable micromotors with versatile biomedical applications. Moreover, we discuss micromotors’ efficacy in detecting and destroying environmental pollutants. Finally, we address the limitations and future research directions of degradable metallic micromotors.

255

项与 Swiss Federal Institute of Technology 相关的新闻（医药）

2024-10-27

·生物谷

生物间的奇妙合作——内共生！Nature | 通过在真菌中注入细菌诱导新的内共生

内共生（endosymbiosis）是一种生物生活在另一种生物内部的奇妙生物现象。这种不寻常的关系往往对双方都有益。即使在我们的体内，我们也能找到这种共生关系的遗迹：线粒体就是由古老的内共生进化而来的。很久以前，细菌进入其他细胞并停留下来，这种共生奠定了线粒体的基础，进而形成了植物、动物和真菌的细胞。然而，人们对内共生这种生活方式究竟是如何产生的仍然知之甚少。一个细菌如果意外地进入了一个完全不同的宿主细胞，通常会过得很艰难。它需要生存、繁殖并传给下一代。否则，它就会死亡。而且，为了不伤害宿主，它不能为自己索取过多的营养，也不能生长得太快。换句话说，如果宿主和寄居者不能和睦相处，这种关系就会结束。为了研究两种生物之间这种特殊关系的开端，苏黎世联邦理工学院微生物学教授Julia Vorholt领导的一个研究团队在实验室中启动了这种合作关系。他们观察了可能的内共生开始时究竟发生了什么。相关研究结果于2024年10月2日在线发表在Nature期刊上，论文标题为“Inducing novel endosymbioses by implanting bacteria in fungi”。 Vorhelt实验室的博士生Gabriel Giger首先开发了一种方法，在不破坏真菌小孢根霉（Rhizopus microsporus）细胞的情况下将细菌注入其中。他一方面使用了大肠杆菌（E. coli），另一方面使用了栖真菌细菌属（Mycetohabitans）的细菌。栖真菌细菌属的细菌是另一种根霉真菌的天然内共生菌。不过，在实验中，他们使用了一种在自然界中不会形成内共生的菌株。 Giger在显微镜下观察了强制内共生时发生的结果。注入大肠杆菌后，小孢根霉（真菌）和大肠杆菌（细菌）都在继续生长，但后者最终迅速生长，以至于小孢根霉对大肠杆菌产生了免疫反应。小孢根霉通过包裹大肠杆菌来保护自己免受其感染，这防止了大肠杆菌传给下一代真菌。然而，当注射栖真菌细菌属的细菌时，情况并不如此：在小孢根霉（真菌）形成孢子的过程中，一些细菌设法进入了孢子，从而传给了下一代。Giger说：“这些细菌实际上是通过孢子传播给下一代真菌的，这是我们研究中的一个突破。” 图：注射M. rhizoxinica会导致内生菌的垂直传播适应与进化当Giger让带有常驻细菌的孢子发芽时，他发现孢子发芽的频率降低了，而且它们的生长速度也比没有常驻细菌的孢子慢。他解释说：“内共生最初降低了受影响真菌的总体适应性。”Giger继续对几代真菌进行实验，有意选择孢子中含有细菌的真菌。这使得这种真菌得以恢复，并产生更多含有细菌但有生命力的孢子。他们通过基因分析表明，这种真菌在实验过程中发生了变化，适应了定居在内部的细菌。作者还发现，驻留细菌与宿主真菌一起产生了生物活性分子，这些分子可以帮助宿主真菌获得营养，抵御线虫或变形虫等天敌。Vorholt强调说：“因此，最初的劣势可以变成优势。” 脆弱的系统作者在他们的研究中展示了早期内共生系统的脆弱性。Giger说：“在自然条件下，宿主真菌的适应能力最初会下降，这可能意味着这种内共生系统的早期消亡。”Vorholt说：“新的内共生系统要想出现并稳定下来，就必须有共生的优势。实现这一点的先决条件是，未来的常驻生物带来有利于内共生的特性。对于宿主来说，这是一个通过吸收另一种生物而一举获得新特性的机会，即使这需要适应。” Vorholt强调说：“在进化过程中，内共生现象显示了它们最终会变得多么成功。”这项研究不仅揭示了内共生的初始阶段，还为我们理解生物间的复杂关系提供了新的视角。参考资料： Gabriel H. Giger et al. Inducing novel endosymbioses by implanting bacteria in fungi. Nature, 2024, doi:10.1038/s41586-024-08010-x. 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

微生物疗法

2024-10-25

·PRNewswire

Meret Gaugler, PhD, joins Page Therapeutics as independent member of the Board of Directors

BASEL, Switzerland, Oct. 25, 2024 /PRNewswire/ -- Page Therapeutics, a biotech company focused on tackling metastatic cancer spread at its root, is pleased to announce the appointment of Meret Gaugler, PhD, as independent member of the Board of Directors. Dr. Gaugler comes with both a scientific background and nearly a decade and a half of experience as an investor both in public and private Life Sciences companies. She is currently acting as a Partner-at-Large in Growth Investments for Novo Holdings, a senior advisor on Life Sciences strategy for Ontario Teachers' Pension Plan as well as serving as an independent advisor and board member. "Meret will bring us invaluable strategic insights as we are moving from an early-stage discovery company to a structured biotech, preparing our drug candidate for clinical trials" commented Nicola Aceto, Professor of Molecular Oncology at ETH Zurich and Page's scientific founder. "Our innovative approach targeting the dissociation of circulating tumour cell clusters to inhibit their potential to form metastases needs a strict development process as well as long term vision and lateral thinking. Meret is a perfect addition to the Board as she brings both these sets of skills" On the Board of Page, Dr. Gaugler joins Prof. Nicola Aceto, scientific founder, Prof. Christoph Rochlitz, MD, co-founder and CMO, as well as Daniele Scarinci, President and CEO and Ciro Spedaliere, the last two representing the financial investors XGEN Venture and Claris Ventures, who have supported the current Seed round of financing. "Page's approach to fighting cancer is extremely insightful and entirely novel" said Dr. Meret Gaugler. "The science behind it and the preclinical evidence shown so far are impressive. Unusual for a company at this stage of development, it has already a clinical proof of concept generated by Prof. Aceto with an existing drug that has a similar mode of action as the company's new molecules. If their approach continues to yield the benefits we are hoping for, we might be setting a new bar in cancer treatment. I am truly looking forward to contributing to the next phases of Page's development." About Page Page Therapeutics ag (" Page") is a Swiss preclinical-stage biotech company spun out of the ETHZ and founded on the groundbreaking science of Prof. Nicola Aceto. Page targets the vulnerabilities of tumour cells circulating in the bloodstream and is developing novel therapies that can disrupt their clusters, inhibiting their ability to form metastases. Media Contact [email protected] Logo: SOURCE PAGE Therapeutics AG WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2024-10-15

·PRNewswire

Cytosurge and Lexogen Partner to Advance Live-Cell Sequencing

Collaboration to Enable Sequencing of Cellular Biopsies ZÜRICH and VIENNA, Oct. 15, 2024 /PRNewswire/ -- Cytosurge AG, a leader in single-cell manipulation, and Lexogen, a pioneer in RNA sequencing solutions, have announced their partnership to advance live-cell sequencing (Live-seq). The collaboration integrates Cytosurge's FluidFM® OMNIUM platform with Lexogen's LUTHOR HD kit to offer a streamlined workflow that preserves cell viability, making live-cell sequencing more accessible and scalable for researchers. For more details, download the shared application note. Continue Reading Cytosurge Logo Live-seq is a groundbreaking technology developed at ETH Zurich and EPFL, Switzerland, that allows the sequencing of a cell's transcriptome while keeping the cell alive. This represents a paradigm shift from traditional methods that kill cells during sampling, providing new opportunities for dynamic, time-resolved transcriptomic studies. Cytosurge's FluidFM® technology enables gentle extraction of cytoplasmic biopsies without harming the cell. Extremely low amounts of RNA (typically <1 pg) in such biopsies demand exceptionally sensitive RNA-Seq library preparation which is where Lexogen's LUTHOR HD kit excels. LUTHOR detects thousands of genes from RNA quantities as low as 0.15 pg - well below the total RNA content of a cell - and thus ideal for Live-seq. Driving Progress toward Scalable and Complete Live-seq Solutions The partnership aims to provide a scalable, easy-to-use workflow for Live-seq, allowing researchers to analyze the transcriptomes of individual cells over time, track gene expression changes in living cells without disrupting their natural processes, and potentially lead to breakthroughs in cellular biology and therapeutic development. "Partnering with Lexogen is a crucial step in advancing our mission of providing precise single-cell analysis," said Pascal Behr, Ph.D., CEO of Cytosurge. "The combination of our FluidFM® technology and Lexogen's ultra-sensitive library prep kit allows us to deliver a comprehensive, end-to-end solution for Live-seq, opening new avenues in transcriptomics research." Lexogen's LUTHOR HD technology uses THOR® amplification ensuring reliable results even with minimal RNA input. When combined with the FluidFM to collect RNA-containing biopsies from living cells, it enables researchers to analyze complex cellular processes with unprecedented sensitivity. "This partnership opens new possibilities to track how individual cells change over time, especially in fields like cancer research, where subtle changes in cell populations can have significant implications," said Filippo Passardi, Ph.D., Product Manager at Lexogen. Cytosurge and Lexogen already share promising results demonstrating the generation of high-quality transcriptome data using LUTHOR HD on biopsies collected via the FluidFM® OMNIUM platform. "This partnership is not only advancing our offerings but has the potential to revolutionize transcriptomics research," added Dario Ossola, Ph.D., Product Manager at Cytosurge. Future Developments The collaboration will focus on analyzing more cell types and expanding the Live-seq workflow to support multiple time points. Both companies are committed to making this technology available to a wider audience, providing an affordable, scalable solution for labs around the world. About Cytosurge Cytosurge AG develops innovative solutions using FluidFM® technology for single-cell manipulation. Their platform combines microfluidics and force feedback, enabling delicate cell interactions that enhance the understanding of cellular processes. With over 120 FluidFM® systems installed globally, Cytosurge is at the forefront of single-cell research. About Lexogen Lexogen is a leader in RNA sequencing, providing cutting-edge solutions for transcriptomics research. Their products are designed to meet the needs of the scientific community, offering end-to-end solutions that deliver high-quality, reliable results. For more information, visit Cytosurge's and Lexogen's websites. Contacts Cytosurge AG Sabina Packeiser, PhD, Head of Marketing Phone +41 43 544 87 00 Email: [email protected] Lexogen Amra Dedic Brand and Event Manager Phone +43 660 69 66 045 Email: [email protected] Logo - Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 Swiss Federal Institute of Technology 相关的药物交易

登录后查看更多信息

100 项与 Swiss Federal Institute of Technology 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月26日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Debio-1124 ( CCKB )	呼吸道肿瘤更多	临床1期
225Ac-PP-F11N ( CCKB )	鳞状细胞癌更多	临床前
[11C]MT107 ( CD80 )	诊断试剂更多	临床前
[18F]-FPECMO ( mGluR5 )	神经系统疾病更多	临床前
镥[177Lu]Lu-PSMA-TB-01 ( PSMA )	肿瘤更多	临床前